Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emmanuelle Le Page

Showing results (11-20 of 65) with videos related to

Pageof 7
Sort By:
Journal of Neurology, Neurosurgery, and Psychiatry|September 12, 2007
Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5 year follow-up observational study of 100 consecutive patientsEmmanuelle Le Page, Emmanuelle Leray, Grégory Taurin, et al.
Neurology|August 11, 2022
Assessing the Risk of Relapse Requiring Corticosteroids After In Vitro Fertilization in Women With Multiple SclerosisMarie Mainguy, Hélène Tillaut, Adeline Degremont, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|May 17, 2019
Decreasing impact of late relapses on disability worsening in secondary progressive multiple sclerosisKevin Ahrweiller, Chloé Rousseau, Emmanuelle Le Page, et al.
Journal of Neurology|September 19, 2022
Discontinuation of second- versus first-line disease-modifying treatment in middle-aged patients with multiple sclerosisMaëlle Chappuis, Chloé Rousseau, Emma Bajeux, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 19, 2021
Pregnancy in women with multiple sclerosis in France from 2010 to 2015: Incidence, outcomes, and exposure to disease-modifying therapiesHélène Tillaut, Adeline Degrémont, Sandrine Kerbrat, et al.
Multiple Sclerosis and Related Disorders|March 31, 2023
Switching from natalizumab administration at the day hospital to administration at home. A 1 year prospective study of patient experience and quality of life in 30 consecutive patients with multiple sclerosis (TYSAD-35)Simon Lamy, David Veillard, Hélène Doyen, et al.
Journal of the Neurological Sciences|November 8, 2017
Cognition and quality of life in clinically isolated syndrome patients starting a disease modifying therapy in the QUALICIS study may not predict treatment response at one yearMikael Cohen, Bruno Brochet, Pierre Clavelou, et al.
Journal of Neurochemistry|April 1, 2026
The Kappa Free Light Chains Index in Multiple Sclerosis: From Emerging Evidence to Clinical ApplicationNoé Verchere, Ségolène Roult, Laure Michel, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|September 4, 2018
Co-occurrence of MS and ALS: a clue in favor of common pathophysiological findings?Anne-Marie Guennoc, Maud Pallix-Guyot, Emmanuelle Le Page, et al.
Lancet (London, England)|July 3, 2015
Oral versus intravenous high-dose methylprednisolone for treatment of relapses in patients with multiple sclerosis (COPOUSEP): a randomised, controlled, double-blind, non-inferiority trialEmmanuelle Le Page, David Veillard, David A Laplaud, et al.
Pageof 7

Showing results (11-20 of 65) with videos related to

Sort By:
Pageof 7
Journal of Neurology, Neurosurgery, and Psychiatry|September 12, 2007
Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5 year follow-up observational study of 100 consecutive patientsEmmanuelle Le Page, Emmanuelle Leray, Grégory Taurin, et al.
Neurology|August 11, 2022
Assessing the Risk of Relapse Requiring Corticosteroids After In Vitro Fertilization in Women With Multiple SclerosisMarie Mainguy, Hélène Tillaut, Adeline Degremont, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|May 17, 2019
Decreasing impact of late relapses on disability worsening in secondary progressive multiple sclerosisKevin Ahrweiller, Chloé Rousseau, Emmanuelle Le Page, et al.
Journal of Neurology|September 19, 2022
Discontinuation of second- versus first-line disease-modifying treatment in middle-aged patients with multiple sclerosisMaëlle Chappuis, Chloé Rousseau, Emma Bajeux, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 19, 2021
Pregnancy in women with multiple sclerosis in France from 2010 to 2015: Incidence, outcomes, and exposure to disease-modifying therapiesHélène Tillaut, Adeline Degrémont, Sandrine Kerbrat, et al.
Multiple Sclerosis and Related Disorders|March 31, 2023
Switching from natalizumab administration at the day hospital to administration at home. A 1 year prospective study of patient experience and quality of life in 30 consecutive patients with multiple sclerosis (TYSAD-35)Simon Lamy, David Veillard, Hélène Doyen, et al.
Journal of the Neurological Sciences|November 8, 2017
Cognition and quality of life in clinically isolated syndrome patients starting a disease modifying therapy in the QUALICIS study may not predict treatment response at one yearMikael Cohen, Bruno Brochet, Pierre Clavelou, et al.
Journal of Neurochemistry|April 1, 2026
The Kappa Free Light Chains Index in Multiple Sclerosis: From Emerging Evidence to Clinical ApplicationNoé Verchere, Ségolène Roult, Laure Michel, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|September 4, 2018
Co-occurrence of MS and ALS: a clue in favor of common pathophysiological findings?Anne-Marie Guennoc, Maud Pallix-Guyot, Emmanuelle Le Page, et al.
Lancet (London, England)|July 3, 2015
Oral versus intravenous high-dose methylprednisolone for treatment of relapses in patients with multiple sclerosis (COPOUSEP): a randomised, controlled, double-blind, non-inferiority trialEmmanuelle Le Page, David Veillard, David A Laplaud, et al.
Pageof 7